New Enterprise Associates

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for primary immune deficiencies and cancer. The company's lead candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. It is in Phase III for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, and in Phase Ib for severe congenital neutropenia and Waldenström macroglobulinemia. Additionally, mavorixafor is being explored in Phase IIa trials for clear cell renal cell carcinoma. X4 Pharmaceuticals is also advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 for primary immune deficiencies. The company has partnered with Abbisko Therapeutics Co., Ltd. to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. and rebranded in March 2019.

NODAR, Inc. is a Boston-based company that specializes in manufacturing advanced sensors for various transportation modes, including cars, trucks, drones, ships, trains, and aircraft. Established in 2018, NODAR focuses on developing cutting-edge camera-based 3D vision systems aimed at enhancing the safety and reliability of autonomous vehicles. Their flagship product, Hammerhead, utilizes off-the-shelf cameras to deliver long-range, ultra-precise depth sensing essential for Level 3 and Level 4 autonomous applications. This technology enables critical functionalities such as collision warning, path planning, and automatic emergency braking, while ensuring cost-effectiveness and high performance. NODAR's innovations target automotive, marine, and railway industries, providing solutions that meet the growing demand for reliable 3D sensing technology in the mainstream automotive market.

Proof of Learn is a talent marketplace focused on educating and placing the next generation of developers. Founded in 2021 and based in Boston, the company operates Metacrafters.io, a multichain learn-to-earn platform that teaches users how to write smart contracts and build on-chain applications. The platform aims to provide equal access to education and job opportunities in the emerging Web3 space, utilizing blockchain technology to create a decentralized model for learning. By empowering learners to gain skills, earn rewards, and secure employment, Proof of Learn addresses the growing demand for qualified talent in the digital economy.

Tulip Interfaces, Inc. specializes in creating applications for the manufacturing industry that enhance shop floor operations. Founded in 2012 and based in Somerville, Massachusetts, the company offers a no-code platform that allows organizations to integrate data from various sources, including sensors and existing equipment. This integration facilitates the creation of digital work instructions and provides real-time visibility into operations, including the performance of personnel and machinery. Tulip serves a diverse range of industries, including consumer electronics, pharmaceuticals, apparel, and medical devices, helping companies improve productivity, quality, and operational efficiency. By leveraging advanced technologies such as intelligent hardware sensors, computer vision, and machine learning, Tulip's platform enables organizations to digitally transform their operations and achieve better end-to-end traceability.

Burrow, Inc. is a New York-based furniture company that designs, manufactures, and supplies a range of home furnishings, including customizable sofas, sectionals, loveseats, armchairs, and ottomans, as well as tables, rugs, and various accessories. Founded in 2016, Burrow focuses on creating luxury furniture that is both easy to move and comfortable, utilizing sustainably-sourced hardwood and non-toxic, scratch- and stain-resistant fabrics. The company aims to reinvent the home furnishing experience by offering personalized and durable products that allow customers to avoid traditional retail markups. Burrow sells its items through physical showrooms in several states, including Washington, Massachusetts, Texas, and California, as well as through its online platform. The company's manufacturing facility is located in Mexico City, Mexico.

DataRobot, Inc. develops an automated machine learning platform that empowers enterprises to create predictive models efficiently. Its offerings include DataRobot Cloud, a predictive analytics solution available both in the cloud and on-premises, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. The company also provides DataRobot Enterprise, featuring flexible deployment options, governance, and training services, along with packages designed to accelerate artificial intelligence projects. DataRobot serves a diverse range of industries, including banking, healthcare, manufacturing, and marketing, catering to business analysts, data scientists, and IT professionals. Founded in 2012 and headquartered in Boston, Massachusetts, DataRobot has expanded its operations globally, with offices in major cities such as London, Paris, and Tokyo, and maintains strategic partnerships to enhance its offerings.

Korro Bio Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing nucleic acid-based therapeutics aimed at editing RNA to treat rare and prevalent diseases. Founded in 2018, the company has created a proprietary platform that allows for efficient and selective RNA editing, leveraging natural processes found in multicellular organisms. This innovative approach enables precise modifications to messenger RNA, allowing for targeted changes in protein structure and function across various tissues. By focusing on RNA instead of DNA, Korro Bio aims to enhance the precision and adaptability of genetic medicines, expanding their potential applications in treating a range of medical conditions.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Akouos, Inc. is a biotechnology company based in Boston, Massachusetts, dedicated to developing gene therapies aimed at restoring, improving, and preserving hearing for individuals affected by various inner ear disorders. Founded in 2016, the company utilizes an innovative platform that includes a proprietary adeno-associated viral vector library and a unique delivery method. Its leading product candidate, AK-OTOF, targets hearing loss resulting from mutations in the OTOF gene. Akouos focuses on genetically-defined patient populations, addressing conditions ranging from single genetic mutations to hearing loss caused by ototoxic drugs and aging. The company has established strategic partnerships with key institutions, including Massachusetts Eye and Ear and Lonza, Inc., to advance its mission of providing precision genetic therapies for sensorineural hearing loss.

Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule therapies that are tumor-agnostic. The company’s lead product candidate, BDTX-189, targets non-canonical and oncogenic mutations in ErbB kinases, specifically the epidermal growth factor receptor and tyrosine-protein kinase. In addition to BDTX-189, Black Diamond is developing allosteric-EGFR mutation inhibitors and other early-stage pipeline programs that address allosteric mutations in kinases associated with cancer and rare genetic diseases. The company's approach is centered on its Mutation-Allostery-Pharmacology platform, which aims to create targeted treatments for genetically defined cancers, especially for patients with limited existing treatment options. Founded in 2014 and headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its name change in January 2018.

DataRobot, Inc. develops an automated machine learning platform that empowers enterprises to create predictive models efficiently. Its offerings include DataRobot Cloud, a predictive analytics solution available both in the cloud and on-premises, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. The company also provides DataRobot Enterprise, featuring flexible deployment options, governance, and training services, along with packages designed to accelerate artificial intelligence projects. DataRobot serves a diverse range of industries, including banking, healthcare, manufacturing, and marketing, catering to business analysts, data scientists, and IT professionals. Founded in 2012 and headquartered in Boston, Massachusetts, DataRobot has expanded its operations globally, with offices in major cities such as London, Paris, and Tokyo, and maintains strategic partnerships to enhance its offerings.

Burrow, Inc. is a New York-based furniture company that designs, manufactures, and supplies a range of home furnishings, including customizable sofas, sectionals, loveseats, armchairs, and ottomans, as well as tables, rugs, and various accessories. Founded in 2016, Burrow focuses on creating luxury furniture that is both easy to move and comfortable, utilizing sustainably-sourced hardwood and non-toxic, scratch- and stain-resistant fabrics. The company aims to reinvent the home furnishing experience by offering personalized and durable products that allow customers to avoid traditional retail markups. Burrow sells its items through physical showrooms in several states, including Washington, Massachusetts, Texas, and California, as well as through its online platform. The company's manufacturing facility is located in Mexico City, Mexico.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing and commercializing therapeutics for rare genetic disorders of hemoglobin, including sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing its lead product candidate, IMR-687, which is a highly selective small molecule inhibitor of PDE9. IMR-687 is designed as an oral, once-a-day treatment that aims to modify disease through a multimodal mechanism of action affecting various cell types, including red and white blood cells. Imara is dedicated to addressing the unmet medical needs of patients suffering from these serious hemoglobinopathies.

Tulip Interfaces, Inc. specializes in creating applications for the manufacturing industry that enhance shop floor operations. Founded in 2012 and based in Somerville, Massachusetts, the company offers a no-code platform that allows organizations to integrate data from various sources, including sensors and existing equipment. This integration facilitates the creation of digital work instructions and provides real-time visibility into operations, including the performance of personnel and machinery. Tulip serves a diverse range of industries, including consumer electronics, pharmaceuticals, apparel, and medical devices, helping companies improve productivity, quality, and operational efficiency. By leveraging advanced technologies such as intelligent hardware sensors, computer vision, and machine learning, Tulip's platform enables organizations to digitally transform their operations and achieve better end-to-end traceability.

Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule therapies that are tumor-agnostic. The company’s lead product candidate, BDTX-189, targets non-canonical and oncogenic mutations in ErbB kinases, specifically the epidermal growth factor receptor and tyrosine-protein kinase. In addition to BDTX-189, Black Diamond is developing allosteric-EGFR mutation inhibitors and other early-stage pipeline programs that address allosteric mutations in kinases associated with cancer and rare genetic diseases. The company's approach is centered on its Mutation-Allostery-Pharmacology platform, which aims to create targeted treatments for genetically defined cancers, especially for patients with limited existing treatment options. Founded in 2014 and headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its name change in January 2018.

DataRobot, Inc. develops an automated machine learning platform that empowers enterprises to create predictive models efficiently. Its offerings include DataRobot Cloud, a predictive analytics solution available both in the cloud and on-premises, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. The company also provides DataRobot Enterprise, featuring flexible deployment options, governance, and training services, along with packages designed to accelerate artificial intelligence projects. DataRobot serves a diverse range of industries, including banking, healthcare, manufacturing, and marketing, catering to business analysts, data scientists, and IT professionals. Founded in 2012 and headquartered in Boston, Massachusetts, DataRobot has expanded its operations globally, with offices in major cities such as London, Paris, and Tokyo, and maintains strategic partnerships to enhance its offerings.

Formlabs Inc. is a company that designs and manufactures advanced 3D printing systems targeted at engineers, designers, and artists. Established in 2011 and headquartered in Somerville, Massachusetts, Formlabs offers a diverse range of products, including the Form 3, Form 3B, and Form 3L printers, all utilizing Low Force Stereolithography (LFS) technology. The company also provides post-processing solutions such as Form Wash and Form Cure, as well as the Fuse 1 SLS 3D printer and the Form Cell manufacturing solution. Formlabs develops high-performance materials for various applications in industries like dental, healthcare, jewelry, and education. Its PreForm software facilitates the preparation of models for printing, making it a preferred choice among professionals worldwide. With additional offices in Germany, Japan, China, Singapore, Hungary, and North Carolina, Formlabs continues to innovate in the field of 3D printing, enhancing the capabilities of digital fabrication.

Tamr, Inc. is an enterprise data unification company that specializes in providing data management solutions. The company offers a platform that utilizes machine learning combined with human expertise to identify and integrate diverse internal and external data sources, thereby enabling organizations to manage siloed data effectively. Tamr's services include enterprise data preparation, clinical data conversion, procurement optimization, and customer data integration, catering to various sectors such as financial services, life sciences, government, and manufacturing. Founded in 2013 by experienced professionals in the database industry, Tamr is headquartered in Cambridge, Massachusetts, with additional offices in major cities including New York, Seattle, San Francisco, Washington, D.C., and London. The company aims to deliver valuable insights from data, supporting clients in achieving successful business outcomes.

Automation Anywhere, Inc. is a global leader in Robotic Process Automation (RPA), specializing in AI-powered software solutions that automate repetitive business tasks. The company's cloud-native platform integrates RPA with artificial intelligence, machine learning, and analytics to improve productivity, customer experience, and employee engagement. Key offerings include Automation Anywhere Enterprise, which automates IT and business processes; Automation Anywhere Server; and the Premier application for creating and managing automation visually. The company also provides solutions like Process inVision for documenting processes and various Testing Anywhere products for quality assurance across multiple platforms. Additionally, Automation Anywhere offers consulting services and has established a strategic partnership with Microsoft Azure. Founded in 2003 and headquartered in San Jose, California, the company operates offices in major global cities, including Boston, Dallas, New York, and various locations in Asia and Europe.

Catalog is a developer of a data conversion and storage platform used to offer the next generation of digital data archives and computation. Its platform facilitates the encoding of data and information into DNA format and makes it economically attractive to use DNA as the major medium for long-term archival of data that enables customers to store digital information in DNA molecules. It brings cutting-edge synthetic biology technologies to the world of information storage and computation. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

Burrow, Inc. is a New York-based furniture company that designs, manufactures, and supplies a range of home furnishings, including customizable sofas, sectionals, loveseats, armchairs, and ottomans, as well as tables, rugs, and various accessories. Founded in 2016, Burrow focuses on creating luxury furniture that is both easy to move and comfortable, utilizing sustainably-sourced hardwood and non-toxic, scratch- and stain-resistant fabrics. The company aims to reinvent the home furnishing experience by offering personalized and durable products that allow customers to avoid traditional retail markups. Burrow sells its items through physical showrooms in several states, including Washington, Massachusetts, Texas, and California, as well as through its online platform. The company's manufacturing facility is located in Mexico City, Mexico.

Upskill, Inc. specializes in designing and developing augmented reality software tailored for the industrial workforce. The company's flagship platform, Skylight, empowers businesses to create applications for smart glasses, facilitating enhanced communication and access to information for hands-on workers across various sectors, such as manufacturing, healthcare, logistics, and military. By connecting workers to essential processes, tools, and data, Skylight aims to improve operational efficiency, reduce errors, and streamline training for new employees. Upskill's innovative solutions enable organizations to increase productivity, enhance quality, and maintain competitiveness in a rapidly evolving market. Founded in 2010 and based in Vienna, Virginia, with additional offices in Cambridge and San Francisco, Upskill was formerly known as APX Labs before rebranding in 2017.

Centrexion Therapeutics Corporation is a late clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing non-opioid and non-addictive therapies aimed at addressing chronic pain. The company's product pipeline includes CNTX-4975, currently in Phase III trials for moderate to severe knee osteoarthritis pain, and in Phase II trials for Morton’s neuroma and canine osteoarthritis. Additionally, CNTX-0290 is in Phase I trials targeting chronic pain associated with inflammatory, neuropathic, and mixed conditions. Other candidates under development include CNTX-6970, for inflammatory pain, and CNTX-2022, a high-concentration topical gel formulation of lidocaine for various types of pain. CNTX-6016 is also in pre-clinical stages focusing on chronic neuropathic pain. Founded in 2013, Centrexion Therapeutics aims to provide safe and effective solutions for patients suffering from chronic pain conditions.

Korro Bio Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing nucleic acid-based therapeutics aimed at editing RNA to treat rare and prevalent diseases. Founded in 2018, the company has created a proprietary platform that allows for efficient and selective RNA editing, leveraging natural processes found in multicellular organisms. This innovative approach enables precise modifications to messenger RNA, allowing for targeted changes in protein structure and function across various tissues. By focusing on RNA instead of DNA, Korro Bio aims to enhance the precision and adaptability of genetic medicines, expanding their potential applications in treating a range of medical conditions.

Akouos, Inc. is a biotechnology company based in Boston, Massachusetts, dedicated to developing gene therapies aimed at restoring, improving, and preserving hearing for individuals affected by various inner ear disorders. Founded in 2016, the company utilizes an innovative platform that includes a proprietary adeno-associated viral vector library and a unique delivery method. Its leading product candidate, AK-OTOF, targets hearing loss resulting from mutations in the OTOF gene. Akouos focuses on genetically-defined patient populations, addressing conditions ranging from single genetic mutations to hearing loss caused by ototoxic drugs and aging. The company has established strategic partnerships with key institutions, including Massachusetts Eye and Ear and Lonza, Inc., to advance its mission of providing precision genetic therapies for sensorineural hearing loss.

DataRobot, Inc. develops an automated machine learning platform that empowers enterprises to create predictive models efficiently. Its offerings include DataRobot Cloud, a predictive analytics solution available both in the cloud and on-premises, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. The company also provides DataRobot Enterprise, featuring flexible deployment options, governance, and training services, along with packages designed to accelerate artificial intelligence projects. DataRobot serves a diverse range of industries, including banking, healthcare, manufacturing, and marketing, catering to business analysts, data scientists, and IT professionals. Founded in 2012 and headquartered in Boston, Massachusetts, DataRobot has expanded its operations globally, with offices in major cities such as London, Paris, and Tokyo, and maintains strategic partnerships to enhance its offerings.

Catalog is a developer of a data conversion and storage platform used to offer the next generation of digital data archives and computation. Its platform facilitates the encoding of data and information into DNA format and makes it economically attractive to use DNA as the major medium for long-term archival of data that enables customers to store digital information in DNA molecules. It brings cutting-edge synthetic biology technologies to the world of information storage and computation. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

Tulip Interfaces, Inc. specializes in creating applications for the manufacturing industry that enhance shop floor operations. Founded in 2012 and based in Somerville, Massachusetts, the company offers a no-code platform that allows organizations to integrate data from various sources, including sensors and existing equipment. This integration facilitates the creation of digital work instructions and provides real-time visibility into operations, including the performance of personnel and machinery. Tulip serves a diverse range of industries, including consumer electronics, pharmaceuticals, apparel, and medical devices, helping companies improve productivity, quality, and operational efficiency. By leveraging advanced technologies such as intelligent hardware sensors, computer vision, and machine learning, Tulip's platform enables organizations to digitally transform their operations and achieve better end-to-end traceability.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Upskill, Inc. specializes in designing and developing augmented reality software tailored for the industrial workforce. The company's flagship platform, Skylight, empowers businesses to create applications for smart glasses, facilitating enhanced communication and access to information for hands-on workers across various sectors, such as manufacturing, healthcare, logistics, and military. By connecting workers to essential processes, tools, and data, Skylight aims to improve operational efficiency, reduce errors, and streamline training for new employees. Upskill's innovative solutions enable organizations to increase productivity, enhance quality, and maintain competitiveness in a rapidly evolving market. Founded in 2010 and based in Vienna, Virginia, with additional offices in Cambridge and San Francisco, Upskill was formerly known as APX Labs before rebranding in 2017.

Desktop Metal, Inc. specializes in additive manufacturing solutions, providing innovative 3D printing technologies tailored for engineers, designers, and manufacturers across various industries. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers a range of products, including the Production System for industrial manufacturing, the Shop System for metal additive manufacturing in machine and job shops, the Studio System for office-based metal 3D printing, and the Fiber desktop 3D printer. Its technologies cater to sectors such as automotive, aerospace, healthcare, consumer products, and heavy industry, enabling on-demand digital mass production that emphasizes speed, cost-efficiency, and high-quality parts. Desktop Metal operates in markets across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, with the majority of its revenue generated from the Americas.

ClearMotion, Inc. is an automotive technology company that specializes in developing advanced suspension systems to enhance vehicle comfort and handling. Founded out of MIT in 2008 and based in Billerica, Massachusetts, with operations in Nuneaton, United Kingdom, ClearMotion integrates hardware and software to create a proactive ride system that anticipates and counteracts shocks and vibrations from uneven road surfaces. This innovative technology not only improves ride quality but also enhances the overall user experience in vehicles. By mapping road surfaces in real-time, ClearMotion's system can mitigate the effects of road roughness almost instantaneously, ensuring a smoother ride for both drivers and passengers.

Docent Health, based in Cambridge, Massachusetts, develops an enterprise consumer engagement platform aimed at enhancing patient care. The company focuses on helping health systems build and maintain lasting relationships with patients by integrating advanced consumer technology and hospitality-inspired service. Its platform combines digital and human interactions to provide personalized support through real-time text messaging, ensuring that patients receive empathetic and tailored experiences related to their clinical care. By leveraging best practices from various industries, Docent Health seeks to promote customer-centric care, ultimately increasing patient lifetime value and assisting healthcare organizations in expanding their market share.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

AVEO Oncology is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing and marketing targeted therapies for cancer. Its lead product, tivozanib, marketed as FOTIVDA, is an oral, once-daily vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used for treating renal cell carcinoma (RCC). The company has completed a Phase III trial of tivozanib and is investigating its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, AVEO is developing Ficlatuzumab, an antibody targeting hepatocyte growth factor, currently in Phase II trials for several cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company also has preclinical products aimed at cachexia and pulmonary arterial hypertension. AVEO collaborates with various pharmaceutical companies to enhance its research and development efforts. Established in 2001, AVEO Oncology aims to address unmet medical needs in oncology through its innovative therapies.

Desktop Metal, Inc. specializes in additive manufacturing solutions, providing innovative 3D printing technologies tailored for engineers, designers, and manufacturers across various industries. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers a range of products, including the Production System for industrial manufacturing, the Shop System for metal additive manufacturing in machine and job shops, the Studio System for office-based metal 3D printing, and the Fiber desktop 3D printer. Its technologies cater to sectors such as automotive, aerospace, healthcare, consumer products, and heavy industry, enabling on-demand digital mass production that emphasizes speed, cost-efficiency, and high-quality parts. Desktop Metal operates in markets across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, with the majority of its revenue generated from the Americas.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing and commercializing therapeutics for rare genetic disorders of hemoglobin, including sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing its lead product candidate, IMR-687, which is a highly selective small molecule inhibitor of PDE9. IMR-687 is designed as an oral, once-a-day treatment that aims to modify disease through a multimodal mechanism of action affecting various cell types, including red and white blood cells. Imara is dedicated to addressing the unmet medical needs of patients suffering from these serious hemoglobinopathies.

Founded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients. TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications. Phase 3 clinical testing of rolapitant is planned to commence during 2011 and the first ALK inhibitor clinical trial is targeted to begin in 2012. TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion. TESARO is headquartered in Waltham, Massachusetts.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

DataRobot, Inc. develops an automated machine learning platform that empowers enterprises to create predictive models efficiently. Its offerings include DataRobot Cloud, a predictive analytics solution available both in the cloud and on-premises, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. The company also provides DataRobot Enterprise, featuring flexible deployment options, governance, and training services, along with packages designed to accelerate artificial intelligence projects. DataRobot serves a diverse range of industries, including banking, healthcare, manufacturing, and marketing, catering to business analysts, data scientists, and IT professionals. Founded in 2012 and headquartered in Boston, Massachusetts, DataRobot has expanded its operations globally, with offices in major cities such as London, Paris, and Tokyo, and maintains strategic partnerships to enhance its offerings.

Docent Health, based in Cambridge, Massachusetts, develops an enterprise consumer engagement platform aimed at enhancing patient care. The company focuses on helping health systems build and maintain lasting relationships with patients by integrating advanced consumer technology and hospitality-inspired service. Its platform combines digital and human interactions to provide personalized support through real-time text messaging, ensuring that patients receive empathetic and tailored experiences related to their clinical care. By leveraging best practices from various industries, Docent Health seeks to promote customer-centric care, ultimately increasing patient lifetime value and assisting healthcare organizations in expanding their market share.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing and commercializing therapeutics for rare genetic disorders of hemoglobin, including sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing its lead product candidate, IMR-687, which is a highly selective small molecule inhibitor of PDE9. IMR-687 is designed as an oral, once-a-day treatment that aims to modify disease through a multimodal mechanism of action affecting various cell types, including red and white blood cells. Imara is dedicated to addressing the unmet medical needs of patients suffering from these serious hemoglobinopathies.

AVEO Oncology is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing and marketing targeted therapies for cancer. Its lead product, tivozanib, marketed as FOTIVDA, is an oral, once-daily vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used for treating renal cell carcinoma (RCC). The company has completed a Phase III trial of tivozanib and is investigating its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, AVEO is developing Ficlatuzumab, an antibody targeting hepatocyte growth factor, currently in Phase II trials for several cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company also has preclinical products aimed at cachexia and pulmonary arterial hypertension. AVEO collaborates with various pharmaceutical companies to enhance its research and development efforts. Established in 2001, AVEO Oncology aims to address unmet medical needs in oncology through its innovative therapies.

Upskill, Inc. specializes in designing and developing augmented reality software tailored for the industrial workforce. The company's flagship platform, Skylight, empowers businesses to create applications for smart glasses, facilitating enhanced communication and access to information for hands-on workers across various sectors, such as manufacturing, healthcare, logistics, and military. By connecting workers to essential processes, tools, and data, Skylight aims to improve operational efficiency, reduce errors, and streamline training for new employees. Upskill's innovative solutions enable organizations to increase productivity, enhance quality, and maintain competitiveness in a rapidly evolving market. Founded in 2010 and based in Vienna, Virginia, with additional offices in Cambridge and San Francisco, Upskill was formerly known as APX Labs before rebranding in 2017.

Desktop Metal, Inc. specializes in additive manufacturing solutions, providing innovative 3D printing technologies tailored for engineers, designers, and manufacturers across various industries. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers a range of products, including the Production System for industrial manufacturing, the Shop System for metal additive manufacturing in machine and job shops, the Studio System for office-based metal 3D printing, and the Fiber desktop 3D printer. Its technologies cater to sectors such as automotive, aerospace, healthcare, consumer products, and heavy industry, enabling on-demand digital mass production that emphasizes speed, cost-efficiency, and high-quality parts. Desktop Metal operates in markets across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, with the majority of its revenue generated from the Americas.

GLAMSQUAD, also known as GLAM Group, is a provider of on-demand beauty services based in New York City, operating since 2013. The company offers a range of services, including hair, makeup, and nail care, catering to clients in various locations such as New York City, Los Angeles, Miami, Washington D.C., Boston, and the San Francisco Bay Area. GLAMSQUAD connects clients with trained and vetted beauty professionals, ensuring high-quality results in the comfort of their homes, at events, or in offices. Clients can conveniently book services through the GLAMSQUAD app or website by selecting a service, date, and time. Additionally, GLAMSQUAD has expanded its offerings to include a line of hair and makeup products, designed based on customer feedback, which can be purchased online or through the app. The company aims to provide personalized beauty experiences while establishing a new retail channel that enhances the connection between beauty professionals and enthusiasts.

Acquia Inc. is a provider of a cloud-based platform that enables organizations to build, deliver, and optimize digital experiences. Founded in 2007 and headquartered in Boston, Massachusetts, Acquia serves a diverse range of industries, including government, higher education, and media, by offering solutions that enhance customer engagement through personalized and contextually relevant content. Its flagship product, Acquia Cloud, is a Platform-as-a-Service tailored for Drupal websites, complemented by tools such as Acquia Lift for creating brand sites, Acquia Content Hub for multi-channel content distribution, and Acquia Journey for data-driven customer journeys. The company also offers a suite of services including project discovery, site audits, and technical support, which help organizations streamline their digital strategies and improve productivity. With a global client base that includes notable organizations like BBC and Nasdaq, Acquia is positioned as a leader in the digital experience management market.

Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.

Ra Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing therapeutics for diseases associated with the overactivation of the complement system. Utilizing a peptide chemistry platform, the company creates synthetic macrocyclic peptides that combine the specificity of antibodies with the pharmacological advantages of small molecules. Its lead candidate, Zilucoplan, is an injectable treatment that has completed Phase II clinical trials for generalized myasthenia gravis and paroxysmal nocturnal hemoglobinuria, along with a Phase Ib trial for patients with renal impairment. Additionally, Ra Pharmaceuticals is advancing pre-clinical programs targeting Factor D inhibition for C3 glomerulonephritis and other complement factors for various diseases. The company has established a collaboration with Merck & Co., Inc. to explore orally available cyclic peptides for non-complement cardiovascular targets. Founded in 2008, Ra Pharmaceuticals operates as a subsidiary of UCB SA.

Tamr, Inc. is an enterprise data unification company that specializes in providing data management solutions. The company offers a platform that utilizes machine learning combined with human expertise to identify and integrate diverse internal and external data sources, thereby enabling organizations to manage siloed data effectively. Tamr's services include enterprise data preparation, clinical data conversion, procurement optimization, and customer data integration, catering to various sectors such as financial services, life sciences, government, and manufacturing. Founded in 2013 by experienced professionals in the database industry, Tamr is headquartered in Cambridge, Massachusetts, with additional offices in major cities including New York, Seattle, San Francisco, Washington, D.C., and London. The company aims to deliver valuable insights from data, supporting clients in achieving successful business outcomes.

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapeutics that target the disease-promoting microenvironment associated with fibrotic diseases and cancer. Established in 2011 and based in Waltham, Massachusetts, the company is engaged in creating pharmaceutical preparations aimed at diagnosing and treating oncological, tumor, and inflammatory diseases. XTuit Pharmaceuticals employs novel strategies to enhance cancer therapy by specifically addressing the tumor microenvironment. Its drug development pipeline includes innovative approaches that inhibit extracellular matrix synthesis and stabilize activated stromal cells, utilizing a clinical biomarker platform for effective treatment outcomes.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

GuideSpark, Inc. specializes in employee communication software aimed at enhancing engagement within organizations. Its primary offering, GuideSpark Communicate Cloud, allows human resource teams to implement communication campaigns and create multi-format content experiences that foster the adoption of HR programs. The platform addresses various HR challenges including benefits, performance management, and compensation. Additionally, GuideSpark provides resources for Total Rewards communication, talent management, and company culture communication, all designed to deepen employee appreciation for organizational investments and clarify their roles within the company. Founded in 2008 and headquartered in Redwood City, California, GuideSpark also has offices in Portland, Boston, San Francisco, and New York. The company serves over 1,000 enterprise customers, facilitating change communications that help align employee behavior with critical business objectives.

Surface Oncology, Inc. is a clinical-stage immuno-oncology company focused on developing innovative cancer therapies. The company is advancing a pipeline of monoclonal antibodies, including SRF231, which inhibits CD47; NZV930, targeting CD73; SRF617, aimed at CD39; SRF388, which targets interleukin 27; and SRF813, focused on CD112R. Additionally, Surface is exploring earlier-stage programs that address critical elements of the tumor microenvironment, such as regulatory T cells and natural killer cells. The company has established collaborations with notable partners, including Novartis Institutes for Biomedical Research for cancer therapy development and Merck Sharp & Dohme Corp. to assess the safety and efficacy of combining SRF617 with KEYTRUDA, an anti-PD-1 therapy. Founded in 2014 and headquartered in Cambridge, Massachusetts, Surface Oncology aims to create conditions that enhance anti-tumor immune responses through its targeted approaches in cancer immunotherapy.

ClearMotion, Inc. is an automotive technology company that specializes in developing advanced suspension systems to enhance vehicle comfort and handling. Founded out of MIT in 2008 and based in Billerica, Massachusetts, with operations in Nuneaton, United Kingdom, ClearMotion integrates hardware and software to create a proactive ride system that anticipates and counteracts shocks and vibrations from uneven road surfaces. This innovative technology not only improves ride quality but also enhances the overall user experience in vehicles. By mapping road surfaces in real-time, ClearMotion's system can mitigate the effects of road roughness almost instantaneously, ensuring a smoother ride for both drivers and passengers.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

DataRobot, Inc. develops an automated machine learning platform that empowers enterprises to create predictive models efficiently. Its offerings include DataRobot Cloud, a predictive analytics solution available both in the cloud and on-premises, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. The company also provides DataRobot Enterprise, featuring flexible deployment options, governance, and training services, along with packages designed to accelerate artificial intelligence projects. DataRobot serves a diverse range of industries, including banking, healthcare, manufacturing, and marketing, catering to business analysts, data scientists, and IT professionals. Founded in 2012 and headquartered in Boston, Massachusetts, DataRobot has expanded its operations globally, with offices in major cities such as London, Paris, and Tokyo, and maintains strategic partnerships to enhance its offerings.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Solace Therapeutics, Inc. is a medical device company focused on developing non-surgical treatments for common bladder disorders, including stress urinary incontinence, overactive bladder, male voiding dysfunction, and lower urinary tract symptoms. The company offers the Vesair Bladder Control System, a lightweight device designed to float within the urinary bladder and effectively reduce involuntary urinary leakage. Solace Therapeutics aims to enhance patient quality of life by providing an office-based therapy that avoids the side effects often associated with traditional drug and surgical options. This innovative approach does not require anesthesia or significant lifestyle changes and is reversible at any time. Established in 2002, Solace Therapeutics is headquartered in Framingham, Massachusetts.

Acquia Inc. is a provider of a cloud-based platform that enables organizations to build, deliver, and optimize digital experiences. Founded in 2007 and headquartered in Boston, Massachusetts, Acquia serves a diverse range of industries, including government, higher education, and media, by offering solutions that enhance customer engagement through personalized and contextually relevant content. Its flagship product, Acquia Cloud, is a Platform-as-a-Service tailored for Drupal websites, complemented by tools such as Acquia Lift for creating brand sites, Acquia Content Hub for multi-channel content distribution, and Acquia Journey for data-driven customer journeys. The company also offers a suite of services including project discovery, site audits, and technical support, which help organizations streamline their digital strategies and improve productivity. With a global client base that includes notable organizations like BBC and Nasdaq, Acquia is positioned as a leader in the digital experience management market.

Upskill, Inc. specializes in designing and developing augmented reality software tailored for the industrial workforce. The company's flagship platform, Skylight, empowers businesses to create applications for smart glasses, facilitating enhanced communication and access to information for hands-on workers across various sectors, such as manufacturing, healthcare, logistics, and military. By connecting workers to essential processes, tools, and data, Skylight aims to improve operational efficiency, reduce errors, and streamline training for new employees. Upskill's innovative solutions enable organizations to increase productivity, enhance quality, and maintain competitiveness in a rapidly evolving market. Founded in 2010 and based in Vienna, Virginia, with additional offices in Cambridge and San Francisco, Upskill was formerly known as APX Labs before rebranding in 2017.

Tamr, Inc. is an enterprise data unification company that specializes in providing data management solutions. The company offers a platform that utilizes machine learning combined with human expertise to identify and integrate diverse internal and external data sources, thereby enabling organizations to manage siloed data effectively. Tamr's services include enterprise data preparation, clinical data conversion, procurement optimization, and customer data integration, catering to various sectors such as financial services, life sciences, government, and manufacturing. Founded in 2013 by experienced professionals in the database industry, Tamr is headquartered in Cambridge, Massachusetts, with additional offices in major cities including New York, Seattle, San Francisco, Washington, D.C., and London. The company aims to deliver valuable insights from data, supporting clients in achieving successful business outcomes.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Kensho Technologies, Inc. specializes in analytics, artificial intelligence, machine learning, and data visualization systems tailored for global banks and investment institutions. Founded in 2012 and headquartered in Cambridge, Massachusetts, with additional offices in New York, Virginia, and California, Kensho develops financial analytics software that enables scalable analytics solutions for commercial entities. Its offerings include Kensho Applied Mind, an AI software that enhances decision-making by addressing complex financial inquiries in natural language. The company also operates a national security division known as Koto. As of April 2018, Kensho operates as a subsidiary of S&P Global Inc.

GuideSpark, Inc. specializes in employee communication software aimed at enhancing engagement within organizations. Its primary offering, GuideSpark Communicate Cloud, allows human resource teams to implement communication campaigns and create multi-format content experiences that foster the adoption of HR programs. The platform addresses various HR challenges including benefits, performance management, and compensation. Additionally, GuideSpark provides resources for Total Rewards communication, talent management, and company culture communication, all designed to deepen employee appreciation for organizational investments and clarify their roles within the company. Founded in 2008 and headquartered in Redwood City, California, GuideSpark also has offices in Portland, Boston, San Francisco, and New York. The company serves over 1,000 enterprise customers, facilitating change communications that help align employee behavior with critical business objectives.

Influitive Corporation specializes in advocate marketing software solutions for business-to-business (B2B) software and technology firms globally. Its flagship product, AdvocateHub, facilitates the creation of advocate communities where customers, partners, and employees engage in activities such as referrals, reference calls, and product reviews. This platform enhances marketing and sales efforts by harnessing customer enthusiasm and integrating with Salesforce to track participants' activities. In addition to its software, Influitive offers consulting services that provide coaching and training for organizations looking to implement or enhance their advocate marketing strategies. The AdvocateHub software can be accessed via a web portal, integrated into client websites, or used on mobile through the Maven app. Founded in 2010 and based in Toronto, Canada, with additional offices in Menlo Park, California, and Boston, Massachusetts, Influitive aims to help companies build trust and commitment across various communication channels.

Influitive Corporation specializes in advocate marketing software solutions for business-to-business (B2B) software and technology firms globally. Its flagship product, AdvocateHub, facilitates the creation of advocate communities where customers, partners, and employees engage in activities such as referrals, reference calls, and product reviews. This platform enhances marketing and sales efforts by harnessing customer enthusiasm and integrating with Salesforce to track participants' activities. In addition to its software, Influitive offers consulting services that provide coaching and training for organizations looking to implement or enhance their advocate marketing strategies. The AdvocateHub software can be accessed via a web portal, integrated into client websites, or used on mobile through the Maven app. Founded in 2010 and based in Toronto, Canada, with additional offices in Menlo Park, California, and Boston, Massachusetts, Influitive aims to help companies build trust and commitment across various communication channels.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions that require long-term management. The company is known for its innovative Medici Drug Delivery System, which facilitates subcutaneous delivery of therapies for diseases such as type 2 diabetes, obesity, and autoimmune disorders. Its lead product, ITCA 650, is currently in phase 3 clinical trials designed to provide sustained treatment for diabetes through a steady-state dosing system. Additionally, Intarcia's DUROS platform stabilizes and delivers therapeutic proteins and peptides, including devices aimed at treating conditions such as Hepatitis C. Founded in 1997 and originally named BioMedicines, the company rebranded to Intarcia Therapeutics in 2004. It is headquartered in Boston, Massachusetts, with a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions that require long-term management. The company is known for its innovative Medici Drug Delivery System, which facilitates subcutaneous delivery of therapies for diseases such as type 2 diabetes, obesity, and autoimmune disorders. Its lead product, ITCA 650, is currently in phase 3 clinical trials designed to provide sustained treatment for diabetes through a steady-state dosing system. Additionally, Intarcia's DUROS platform stabilizes and delivers therapeutic proteins and peptides, including devices aimed at treating conditions such as Hepatitis C. Founded in 1997 and originally named BioMedicines, the company rebranded to Intarcia Therapeutics in 2004. It is headquartered in Boston, Massachusetts, with a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina.

Influitive Corporation specializes in advocate marketing software solutions for business-to-business (B2B) software and technology firms globally. Its flagship product, AdvocateHub, facilitates the creation of advocate communities where customers, partners, and employees engage in activities such as referrals, reference calls, and product reviews. This platform enhances marketing and sales efforts by harnessing customer enthusiasm and integrating with Salesforce to track participants' activities. In addition to its software, Influitive offers consulting services that provide coaching and training for organizations looking to implement or enhance their advocate marketing strategies. The AdvocateHub software can be accessed via a web portal, integrated into client websites, or used on mobile through the Maven app. Founded in 2010 and based in Toronto, Canada, with additional offices in Menlo Park, California, and Boston, Massachusetts, Influitive aims to help companies build trust and commitment across various communication channels.

Influitive Corporation specializes in advocate marketing software solutions for business-to-business (B2B) software and technology firms globally. Its flagship product, AdvocateHub, facilitates the creation of advocate communities where customers, partners, and employees engage in activities such as referrals, reference calls, and product reviews. This platform enhances marketing and sales efforts by harnessing customer enthusiasm and integrating with Salesforce to track participants' activities. In addition to its software, Influitive offers consulting services that provide coaching and training for organizations looking to implement or enhance their advocate marketing strategies. The AdvocateHub software can be accessed via a web portal, integrated into client websites, or used on mobile through the Maven app. Founded in 2010 and based in Toronto, Canada, with additional offices in Menlo Park, California, and Boston, Massachusetts, Influitive aims to help companies build trust and commitment across various communication channels.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Philo is an entertainment-focused streaming service that provides live access to a variety of cable channels and major broadcasts, allowing users to enjoy shows, live news, sports, and entertainment on their smartphones or computers. The platform enables features such as pausing of live channels, enhancing the viewing experience. Originally founded to cater to the college market, Philo has evolved into a more comprehensive TV platform inspired by Philo T. Farnsworth, the inventor of electronic television. The company is headquartered in San Francisco, with additional offices in New York and Cambridge, Massachusetts. Philo has attracted investments from notable firms and individuals, including New Enterprise Associates, Rho Ventures, and HBO, which support its mission to create an improved television experience.

SingleStore, Inc. is a provider of a relational database designed for cloud and on-premises transactions and analytics. The company offers a cloud database-as-a-service, known as SingleStore Managed Service, which enables analytics on the cloud of choice. Its flagship product, SingleStore DB, is a distributed SQL database that supports operational analytics on bare metal and hybrid cloud environments. SingleStore specializes in modernizing data platforms, securing government workloads, and facilitating IoT analytics, customer interactions, and risk management. It caters to a diverse range of industries, including financial services, media communications, energy, government, and retail. Founded in 2011 and headquartered in San Francisco, California, the company has additional offices in Seattle, Boston, Portland, Lisbon, and London. Initially known as MemSQL Inc., it rebranded to SingleStore, Inc. in October 2020.

Founded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients. TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications. Phase 3 clinical testing of rolapitant is planned to commence during 2011 and the first ALK inhibitor clinical trial is targeted to begin in 2012. TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion. TESARO is headquartered in Waltham, Massachusetts.

Motus Therapeutics is a biotechnology company based in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet medical needs in metabolic diseases, particularly gastrointestinal disorders. The company's lead product candidate, relamorelin, is a ghrelin agonist designed to treat diabetic gastroparesis, a complication associated with diabetes, as well as other gastrointestinal functional disorders. Motus Therapeutics aims to provide innovative solutions for patients suffering from these conditions.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions that require long-term management. The company is known for its innovative Medici Drug Delivery System, which facilitates subcutaneous delivery of therapies for diseases such as type 2 diabetes, obesity, and autoimmune disorders. Its lead product, ITCA 650, is currently in phase 3 clinical trials designed to provide sustained treatment for diabetes through a steady-state dosing system. Additionally, Intarcia's DUROS platform stabilizes and delivers therapeutic proteins and peptides, including devices aimed at treating conditions such as Hepatitis C. Founded in 1997 and originally named BioMedicines, the company rebranded to Intarcia Therapeutics in 2004. It is headquartered in Boston, Massachusetts, with a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina.

Predictive Biosciences, Inc., a molecular diagnostics company, develops diagnostic products for informed cancer management. It specializes in proteomics, diagnostics, oncology, and tumor biomarkers. The company offers biomarkers and proteomics-based assay technologies. These assays detect urinary biomarkers associated with the physiological changes resulting from cancer development and progression. It also provides Triage Monitoring Assay, which allows physicians to delay and invasive diagnostic procedures; Interval Monitoring Assay that is for surveillance and detection of cancer between follow-ups; and Stratification Assay, which supports a physician's decision to manage a patient. Predictive Biosciences, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Founded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients. TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications. Phase 3 clinical testing of rolapitant is planned to commence during 2011 and the first ALK inhibitor clinical trial is targeted to begin in 2012. TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion. TESARO is headquartered in Waltham, Massachusetts.

Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery, development, and commercialization of novel epigenetic medicines for cancer and other serious diseases. The company has developed Tazemetostat, an EZH2 inhibitor approved for the treatment of metastatic or locally advanced epithelioid sarcoma in the United States. Additionally, Tazemetostat is being investigated in combination therapies for various cancers, including relapsed follicular lymphoma and high-risk diffuse large B-cell lymphoma, as well as in patients with platinum-resistant solid tumors and castration-resistant prostate cancer. Epizyme also works on other product candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, along with inhibitors targeting PRMT5 and PRMT1 for different types of cancers. Established in 2007, Epizyme collaborates with several prominent organizations to advance its research and development efforts.

Play Hard Sports, Inc. (Play Hard) is the first casual sports network in North America focused exclusively on developing, publishing and distributing exceptional sports games and entertainment across the Internet. Headquartered in the shadow of the world-famous football stadium at Foxboro, Massachusetts, Play Hard is creating the next-generation in online sports with no massive download, no long waiting for the game to load, and no required fees to play. Play Hard provides its audience with high-quality sports titles that can be played almost anywhere and anytime.

Predictive Biosciences, Inc., a molecular diagnostics company, develops diagnostic products for informed cancer management. It specializes in proteomics, diagnostics, oncology, and tumor biomarkers. The company offers biomarkers and proteomics-based assay technologies. These assays detect urinary biomarkers associated with the physiological changes resulting from cancer development and progression. It also provides Triage Monitoring Assay, which allows physicians to delay and invasive diagnostic procedures; Interval Monitoring Assay that is for surveillance and detection of cancer between follow-ups; and Stratification Assay, which supports a physician's decision to manage a patient. Predictive Biosciences, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Play Hard Sports, Inc. (Play Hard) is the first casual sports network in North America focused exclusively on developing, publishing and distributing exceptional sports games and entertainment across the Internet. Headquartered in the shadow of the world-famous football stadium at Foxboro, Massachusetts, Play Hard is creating the next-generation in online sports with no massive download, no long waiting for the game to load, and no required fees to play. Play Hard provides its audience with high-quality sports titles that can be played almost anywhere and anytime.

Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions that require long-term management. The company is known for its innovative Medici Drug Delivery System, which facilitates subcutaneous delivery of therapies for diseases such as type 2 diabetes, obesity, and autoimmune disorders. Its lead product, ITCA 650, is currently in phase 3 clinical trials designed to provide sustained treatment for diabetes through a steady-state dosing system. Additionally, Intarcia's DUROS platform stabilizes and delivers therapeutic proteins and peptides, including devices aimed at treating conditions such as Hepatitis C. Founded in 1997 and originally named BioMedicines, the company rebranded to Intarcia Therapeutics in 2004. It is headquartered in Boston, Massachusetts, with a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina.

The core analytical platform within the Micro Focus software portfolio, Vertica is the Unified Analytics Platform, based on a massively scalable architecture with the broadest set of analytical capabilities and end-to-end in-database machine learning. Vertica enables many customers – from Philips to The Trade Desk to MassMutual to many others – to easily apply these powerful functions to the largest and most demanding analytical workloads, arming businesses and its customers with predictive business insights faster than any data analytical platform in the market. Vertica provides its Unified Analytics Platform across all major public clouds and on-premises data centers and integrates data in cloud object storage. The company was founded as Stonebraker Systems, Inc. in 2005 and changed its name to Vertica Systems, Inc. in May 2005. The company is headquartered in Billerica, Massachusetts. Vertica's user community has created a Google group. Email Address: vertica_users@googlegroups.com Home Page: http://groups.google.com/group/vertica_users?hl=en

U4EA Wireless, provides WiFi mobility solutions and networking protocol software for the wired and wireless communications market. It offers GateD, a routing and switching software; and wireless controller switching software, for WPA. The company also provides professional services, such as porting, integration, testing, feature acceleration, and product consultation. NextHop offers its products and services to mobile enterprise and carrier equipment manufacturers. It has locations in Ann Arbor, Michigan; and Bangalore, India. The company was founded in 2000 and is headquartered in Mountain View, California. The company also has sales offices in Acton, Massachusetts; Beijing, China; Oxford, the United Kingdom; and Taipei, Taiwan.

PolyServe, Inc. specializes in storage software that consolidates servers and storage into efficient and scalable solutions for database and file serving. Founded in 1999 and headquartered in Beaverton, Oregon, the company provides a Database Utility designed for SQL server consolidation, Oracle, Oracle RAC, and DB2, as well as a File Serving Utility that supports high-performance, scalable NAS, Windows file and print services, web and application clusters, and Oracle. PolyServe's products are marketed through a network of international distributors and direct sales, supported by strategic partnerships with major technology companies. The company was acquired by Hewlett-Packard Co. in March 2007 and has additional offices in various major cities, including Atlanta, Boston, Chicago, and London.

Konarka Technologies, Inc. develops and advances nano-enabled polymer photovoltaic materials for commercial, industrial, government, and consumer applications. It provides standard products to serve portable power needs; and custom solutions, such as roll up chargers, personal accessories, and fold up chargers. The company's products are used in outdoor, portable power, indoor and remote sensing, and mission critical applications. It has strategic partnerships with Air Products, 24 Innovations, Kurz, SkyShades, Chevron, Merck, Toppan Forms, Dupont, Siemens, and the U.S. Air Force. Konarka Technologies, Inc. was founded in 2001 and is headquartered in Lowell, Massachusetts with business development offices in Asia. It has a research and development facility in Austria. The company has operations in the United States, Europe, and Asia.

The core analytical platform within the Micro Focus software portfolio, Vertica is the Unified Analytics Platform, based on a massively scalable architecture with the broadest set of analytical capabilities and end-to-end in-database machine learning. Vertica enables many customers – from Philips to The Trade Desk to MassMutual to many others – to easily apply these powerful functions to the largest and most demanding analytical workloads, arming businesses and its customers with predictive business insights faster than any data analytical platform in the market. Vertica provides its Unified Analytics Platform across all major public clouds and on-premises data centers and integrates data in cloud object storage. The company was founded as Stonebraker Systems, Inc. in 2005 and changed its name to Vertica Systems, Inc. in May 2005. The company is headquartered in Billerica, Massachusetts. Vertica's user community has created a Google group. Email Address: vertica_users@googlegroups.com Home Page: http://groups.google.com/group/vertica_users?hl=en

U4EA Wireless, provides WiFi mobility solutions and networking protocol software for the wired and wireless communications market. It offers GateD, a routing and switching software; and wireless controller switching software, for WPA. The company also provides professional services, such as porting, integration, testing, feature acceleration, and product consultation. NextHop offers its products and services to mobile enterprise and carrier equipment manufacturers. It has locations in Ann Arbor, Michigan; and Bangalore, India. The company was founded in 2000 and is headquartered in Mountain View, California. The company also has sales offices in Acton, Massachusetts; Beijing, China; Oxford, the United Kingdom; and Taipei, Taiwan.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions that require long-term management. The company is known for its innovative Medici Drug Delivery System, which facilitates subcutaneous delivery of therapies for diseases such as type 2 diabetes, obesity, and autoimmune disorders. Its lead product, ITCA 650, is currently in phase 3 clinical trials designed to provide sustained treatment for diabetes through a steady-state dosing system. Additionally, Intarcia's DUROS platform stabilizes and delivers therapeutic proteins and peptides, including devices aimed at treating conditions such as Hepatitis C. Founded in 1997 and originally named BioMedicines, the company rebranded to Intarcia Therapeutics in 2004. It is headquartered in Boston, Massachusetts, with a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina.

PolyServe, Inc. specializes in storage software that consolidates servers and storage into efficient and scalable solutions for database and file serving. Founded in 1999 and headquartered in Beaverton, Oregon, the company provides a Database Utility designed for SQL server consolidation, Oracle, Oracle RAC, and DB2, as well as a File Serving Utility that supports high-performance, scalable NAS, Windows file and print services, web and application clusters, and Oracle. PolyServe's products are marketed through a network of international distributors and direct sales, supported by strategic partnerships with major technology companies. The company was acquired by Hewlett-Packard Co. in March 2007 and has additional offices in various major cities, including Atlanta, Boston, Chicago, and London.

Konarka Technologies, Inc. develops and advances nano-enabled polymer photovoltaic materials for commercial, industrial, government, and consumer applications. It provides standard products to serve portable power needs; and custom solutions, such as roll up chargers, personal accessories, and fold up chargers. The company's products are used in outdoor, portable power, indoor and remote sensing, and mission critical applications. It has strategic partnerships with Air Products, 24 Innovations, Kurz, SkyShades, Chevron, Merck, Toppan Forms, Dupont, Siemens, and the U.S. Air Force. Konarka Technologies, Inc. was founded in 2001 and is headquartered in Lowell, Massachusetts with business development offices in Asia. It has a research and development facility in Austria. The company has operations in the United States, Europe, and Asia.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions that require long-term management. The company is known for its innovative Medici Drug Delivery System, which facilitates subcutaneous delivery of therapies for diseases such as type 2 diabetes, obesity, and autoimmune disorders. Its lead product, ITCA 650, is currently in phase 3 clinical trials designed to provide sustained treatment for diabetes through a steady-state dosing system. Additionally, Intarcia's DUROS platform stabilizes and delivers therapeutic proteins and peptides, including devices aimed at treating conditions such as Hepatitis C. Founded in 1997 and originally named BioMedicines, the company rebranded to Intarcia Therapeutics in 2004. It is headquartered in Boston, Massachusetts, with a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina.

Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Coriolis Networks, headquartered in Boxborough, Mass., began in mid 1999 with a mission to develop a comprehensive approach to the needs of carriers for reliable and scalable optical network solutions. From the beginning, Coriolis Networks realized that success in this market would be based on providing customers with a solution that was compatible with existing SONET network architectures but dramatically improved on the data service delivery capability with new lower price points. Coriolis' target market is the network service provider community on a global basis. Our target customers include competitive and incumbent local exchange carriers, Internet service providers, and wholesale carriers that are building out their fiber-optic facilities to meet their end-user demands for more high-speed data services as well as traditional metro services.

PolyServe, Inc. specializes in storage software that consolidates servers and storage into efficient and scalable solutions for database and file serving. Founded in 1999 and headquartered in Beaverton, Oregon, the company provides a Database Utility designed for SQL server consolidation, Oracle, Oracle RAC, and DB2, as well as a File Serving Utility that supports high-performance, scalable NAS, Windows file and print services, web and application clusters, and Oracle. PolyServe's products are marketed through a network of international distributors and direct sales, supported by strategic partnerships with major technology companies. The company was acquired by Hewlett-Packard Co. in March 2007 and has additional offices in various major cities, including Atlanta, Boston, Chicago, and London.

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's technology and global services are designed to enable life sciences companies to automate and integrate the management of their entire clinical development process, from study initiation and FDA submission through post-marketing studies. Until its acquisition by Oracle in April 2010, Phase Forward was a publicly held company. Its corporate headquarters were in Waltham, Massachusetts, international headquarters in Maidenhead, UK, and its regional offices in the U.S., Japan, France and Australia. Phase Forward was founded in 1997 by Paul Bleicher, M.D, Ph.D., who had experienced firsthand the complexities involved in developing and conducting paper-based trials, in particular, capturing, managing, and growing volumes of data. Dr. Bleicher's vision was to develop technology that would enable organizations to make the shift from paper-based methods to Internet-enabled solutions. His pioneering efforts have contributed significantly to Phase Forward's evolution from initial concept to its current industry-leading position. Spearheading the evolution of electronic data capture (EDC) with its industry-leading InForm solution, Phase Forward transformed the way clinical data are collected, analyzed and managed. With the acquisition of Lincoln Technologies' innovative safety management solutions, Phase Forward took steps to provide the end-to-end solutions customers need to track and monitor product efficacy and safety, while building their trials more efficiently and cost-effectively.

Coriolis Networks, headquartered in Boxborough, Mass., began in mid 1999 with a mission to develop a comprehensive approach to the needs of carriers for reliable and scalable optical network solutions. From the beginning, Coriolis Networks realized that success in this market would be based on providing customers with a solution that was compatible with existing SONET network architectures but dramatically improved on the data service delivery capability with new lower price points. Coriolis' target market is the network service provider community on a global basis. Our target customers include competitive and incumbent local exchange carriers, Internet service providers, and wholesale carriers that are building out their fiber-optic facilities to meet their end-user demands for more high-speed data services as well as traditional metro services.